

# Antidepressants to prevent relapse in depression in older people aged 75 years and over

<b>Submission date</b> 05/07/2024	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 22/08/2024	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 10/09/2024	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Depression is common in older adults and 1 in 7 will become depressed enough to need treatment. Although psychological (talking) therapies can be helpful, many people are treated with antidepressant medication by their general practitioner. Once depression has improved, it is unclear for how long antidepressant treatment should be continued. When patients ask "When can I stop my antidepressant?" their doctors do not have an answer that is based on evidence. Antidepressant drugs can have side effects that can contribute to memory and concentration difficulties and affect the control of blood pressure or the healthy rhythm of the heart. Many people are keen to stop their antidepressants as soon as they can. There is good evidence from studies involving younger people and a small amount of information from older people, that continuing antidepressants for at least 6 months after recovery can help to reduce the risk of depressed mood returning. Some people who have taken an antidepressant will experience withdrawal symptoms in the days and weeks whilst reducing and after stopping treatment. These withdrawal symptoms can sometimes resemble the symptoms of a recurrence of depression and it is important to be able to identify them so that they can be distinguished from each other. The ANTLER clinical trial (<https://www.isrctn.com/ISRCTN15969819>) showed in people aged 18 to 74 years, that continuing antidepressants for 12 months after they had recovered halved the risk they would become depressed again. Depression in people over the age of 75 and the response to treatment are often different from those in younger people. Risk factors for developing depression and continuing to be depressed are different, and older adults are also more likely to have additional physical illnesses as well as diseases affecting the blood supply to the brain that can reduce the effectiveness of depression treatment and increase the side effects of antidepressants. This study is a very similar clinical trial to ANTLER, involving people aged 75 years or older.

### Who can participate?

Patients aged 75 years or older, who are taking antidepressants

### What does the study involve?

Participation in the trial will involve a 50% chance of continuing the antidepressant for 12

months and a 50% chance of reducing and stopping the antidepressant to take a dummy pill (placebo). All trial medication will appear identical so that participants and trial staff remain unaware of what treatment is being taken by an individual in the trial. The most important measure from the trial will be the time at which depression returns during the 12 months of the study, should this occur. The study will also investigate differences in the experience of symptoms of antidepressant withdrawal, anxiety, memory and concentration and side effects of antidepressant medications. From information collected on the quality of life of participants in continuation and discontinuation groups, their use of health and social services and the impact of their depression on their activities and family life, the study will also investigate whether any benefits of continuing treatment also impact on the financial costs of illness. Some participants will be interviewed about their experiences of reducing and stopping treatment.

What are the possible benefits and risks of participating?  
Benefits and risks not provided at time of registration

Where is the study run from?  
University College London CCTU (UK)

When is the study starting and how long is it expected to run for?  
December 2023 to February 2028

Who is funding the study?  
National Institute for Health and Care Research (NIHR) (UK).

Who is the main contact?  
Sue Philpott (Trial Manager), s.philpott@ucl.ac.uk

## Contact information

### Type(s)

Principal investigator

### Contact name

Prof Rob Howard

### Contact details

UCL, Gower Street  
London  
United Kingdom  
WC1E 6BT  
+44 203 35495114  
robert.howard@ucl.ac.uk

### Type(s)

Public, Scientific

### Contact name

Ms Sue Philpott

### Contact details

UCL, Gower Street  
London  
United Kingdom  
WC1E 6BT  
+44 (0)20 7670 4813  
s.philpott@ucl.ac.uk

## **Additional identifiers**

**Integrated Research Application System (IRAS)**  
1009793

**Central Portfolio Management System (CPMS)**  
63558

**Protocol serial number**  
149926

## **Study information**

### **Scientific Title**

Antidepressants to prevent relapse in depression in older people (ANTLER 75+ Trial) – a double blind randomised controlled trial to evaluate the effectiveness and cost-effectiveness of continuing antidepressants

### **Acronym**

ANTLER 75+

### **Study objectives**

To estimate the effectiveness and cost-effectiveness of continuing antidepressant medication for one year compared to discontinuation, in preventing depression relapse in UK primary care in people aged 75 years and older who have had two or more episodes of depression or have been taking antidepressants for at least 2 years, have taken citalopram, mirtazapine or sertraline for at least nine months and are now well enough to consider stopping the antidepressant. This study will compare maintenance antidepressants with discontinuation following a taper period.

To estimate the difference in depression and anxiety symptoms between randomised groups.

To estimate the difference in adverse effects of antidepressants by randomised groups.

To determine the difference in withdrawal symptoms between randomised groups.

To estimate the difference in health-related quality of life between randomised groups.

To compare the relative cost-effectiveness of the two arms of the trial.

To understand older adults' decision-making about antidepressants, their experiences of reducing and stopping antidepressants and withdrawal symptoms.

To understand the perspectives of general practitioners about the diagnosis and management of depression in older adults, prescribing, monitoring and deprescribing antidepressants.

### **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

Approved 19/08/2024, South Central - Hampshire B Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, UK; +44 (0)207 104 8088; hampshireb.rec@hra.nhs.uk); ref: 24/SC/0247

## **Study design**

Multicentre interventional double-blinded randomized controlled trial

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Depression

## **Interventions**

The Intervention will be a continuation of the antidepressant medication that the participants are already taking compared to tapering and discontinuing the antidepressant medication to estimate the effectiveness and cost-effectiveness in preventing depression relapse in people aged 75 and over.

Participants who meet the eligibility criteria and sign the informed consent form will be randomised (using a Sealed Envelope method).

Participants will be randomised into 2 groups: Arm A (Continue with their usual antidepressant) or Arm B (taper off and discontinue usual antidepressants)

Comparator (Arm A): Continued treatment with citalopram 20mg, sertraline 50mg or mirtazapine 30mg using identical appearing study IMP.

Intervention (Arm B): 12 months' discontinuation after tapering in patients receiving treatment with citalopram 20mg, sertraline 50mg or mirtazapine 30mg. Using identical appearing tapering doses of antidepressants and placebos.

For weeks 1-6 participants will be instructed to take 1 capsule a day from a single bottle:

Arm A: (continuation of current antidepressant): usual dose

Arm B: (tapering and discontinuation): half of the usual dose

Weeks 7-12 participants will receive 2 bottles of medication and instructed to take one capsule a day from alternate bottles:

Arm A: usual dose in each bottle

Arm B: half dose in bottle 1 and placebo in bottle 2

Weeks 13-52 participants will be instructed to take 1 capsule a day from a single bottle:

Arm A: usual dose

Arm B: placebo only

All trial IMP will be posted to the participant's home address.

Participants will be followed up during the 12 months with regular telephone assessments and questionnaires.

## **Intervention Type**

Drug

## **Phase**

Phase IV

## **Drug/device/biological/vaccine name(s)**

Citalopram 10mg film-coated tablets [Citalopram hydrobromide] , Citalopram 20mg film-coated tablets [Citalopram hydrobromide] , Mirtazapine 15 mg tablets [Mirtazapine] , Mirtazapine Aurobindo 15mg film-coated tablets [Mirtazapine] , Mirtazapine 30mg tablets [Mirtazapine] , Mirtazapine Aurobindo 30mg film-coated tablets [Mirtazapine] , Sertraline 50mg film-coated tablets [Sertraline hydrochloride] , Sertrone 25mg film-coated tablets [Sertraline hydrochloride]

## **Primary outcome(s)**

The time to first relapse of depression during the 52-week follow-up, as determined in a time-to-event analysis. This will be determined using the Clinician Interview Schedule-Revised (rCIS-R)

## **Key secondary outcome(s)**

1. Depression measured using the Geriatric Depression Scale (GDS-15) at baseline and weeks 8, 16, 24, 32, 40, 48 and 52
2. Symptoms of anxiety measured using the Generalised Anxiety Disorder Assessment 7-item version (GAD7) at baseline and weeks 8, 16, 24, 32, 40, 48 and 52
3. Physical symptoms of side effects of antidepressants measured using the Toronto Side Effect Scale at baseline and weeks 8, 16, 32 and 48 weeks
4. Antidepressant withdrawal effects measured using a modified 17-item version of the Discontinuation-Emergent Signs and Symptoms (DESS) checklist at baseline and weeks 4, 8, 12, 14, 16 and 18
5. Quality of Life Scores for Physical and Mental Health measured using the 12-item Short-Form Survey (SF-12) at baseline and weeks 24 and 52
6. Cognitive Functioning measured using the Montreal Cognitive Assessment (MOCA) at baseline and weeks 24 and 52
7. Adherence to study medication measured using a single question at each follow-up
8. Levels of Fitness-Frailty, polypharmacy and multimorbidity measured using the Pictorial Fit-Frail Scale (PFFS) at baseline and weeks 24 and 52
9. Resource for health and social care measured using a modified version of the Client Service Receipt Inventory (CSRI) at baseline and weeks 24 and 52
10. Health Quality of life measured using the EQ-5D-5L (a five-item, five-level questionnaire) at baseline and weeks 24 and 52
11. Understanding older adults' decision-making about antidepressants and their experience of reducing and stopping measured using qualitative follow-up interviews after collection of primary endpoint data
12. Understanding the perspective of GPs on the diagnosis and management of depression in older adults measured using qualitative interviews after collection of primary endpoint data

## **Completion date**

28/02/2028

## **Eligibility**

### **Key inclusion criteria**

1. Aged 75 years old and over
2. Either 2 or more previous episodes of depression treated with antidepressants (any antidepressant for any length of time) OR taking any antidepressant for at least 2 years at any time
3. Currently has been taking either citalopram, sertraline or mirtazapine for at least 9 months, of which the last 3 months should be at the following doses: 20mg citalopram, 50 mg sertraline or 30mg mirtazapine. These 9 months can be included in the 2 years stated in inclusion 2
4. Currently not depressed (scores <5 on 15-item Geriatric Depression Scale) and are now well enough to consider stopping the antidepressant
5. Presence of a Study Partner (a family member, friend or formal caregiver) who sees or speaks to the participant at least once a week and is prepared to support the completion of outcome measures that involve recall of the previous 8 weeks
6. Provides Informed Consent

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Senior

### **Lower age limit**

75 years

### **Upper age limit**

100 years

### **Sex**

All

### **Key exclusion criteria**

1. Diagnosis of Bipolar Disorder
2. Diagnosis of Dementia (although people with mild cognitive impairment will be eligible for the trial)
3. Currently prescribed a combination of antidepressants or an antidepressant and a mood stabiliser or an antipsychotic as this would indicate individuals with a history of more severe depression who would be at higher risk of relapse of depression
4. Participation in another interventional study
5. Participated in a CTIMP or a trial of psychological intervention in the preceding 3 months

### **Date of first enrolment**

01/11/2024

### **Date of final enrolment**

31/05/2026

# Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

**University College London, Division of Psychiatry**

6th Floor, Wings A and B, Maple House, 149 Tottenham Ct Rd

London

United Kingdom

W1T 7NF

## Study participating centre

-

Manchester

United Kingdom

-

## Study participating centre

-

Nottingham

United Kingdom

-

## Study participating centre

-

Newcastle

United Kingdom

-

## Study participating centre

-

Oxford

United Kingdom

-

## Study participating centre

-  
Keele  
United Kingdom  
-

## Sponsor information

### Organisation

University College London

### ROR

<https://ror.org/02jx3x895>

## Funder(s)

### Funder type

Government

### Funder Name

National Institute for Health and Care Research

### Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date

### IPD sharing plan summary

Not expected to be made available

